RTP Mobile Logo
Dermatologic Oncology Update, Issue 1, 2015
Released December 2015

Featuring interviews with Drs Jeffrey Weber, Michael A Postow, Evan J Lipson and Antoni Ribas. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Taken together, melanoma and nonmelanoma skin cancer — basal cell carcinoma (BCC) and cutaneous squamous cell cancer (SCC) — likely represent the most prevalent form of human cancer. Fortunately, the vast majority of skin cancer presents as minimally invasive BCC and SCC and, as such, is highly curable with local treatment alone. However, in rare instances these characteristically indolent lesions progress and necessitate systemic intervention with the support of limited randomized clinical evidence. In contrast, cancerous melanoma is the most aggressive form of skin cancer with a predilection toward distant metastases, even when identified in the early stages. Thus melanoma and nonmelanoma skin cancer are distinct entities, each posing unique challenges to the oncology community. Featuring up-to-date information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Recognize immune-related adverse events associated with ipilimumab alone or in combination with nivolumab, and offer supportive management strategies to minimize and/or manage these side effects.
    • Use biomarkers, clinical characteristics and mutational analyses to select individualized front-line and subsequent treatment approaches for patients with advanced melanoma.
    • Recall existing and emerging research information demonstrating the effect of combining BRAF and MEK inhibitors for patients with BRAF mutation-positive metastatic melanoma, and use this information to guide treatment planning for these patients.
    • Counsel patients regarding the risk of BRAF inhibitor-associated secondary nonmelanoma skin cancers and other adverse events, and implement appropriate surveillance and management strategies.
    • Appraise the rationale for and clinical trial data with investigational anti-PD-1/PD-L1 antibodies for advanced desmoplastic melanoma.
    • Identify patients with locally advanced or metastatic BCC for whom vismodegib may be an appropriate treatment consideration.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr WeberAdvisory Committee: Abbott Laboratories, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Scientific Advisory Board: Altor Bioscience Corp, Celldex Therapeutics, Lion Biotechnologies; Stock Ownership: Altor Bioscience Corp, Celldex Therapeutics. Dr PostowAdvisory Committee: Amgen Inc, Bristol-Myers Squibb Company; Contracted Research: Bristol-Myers Squibb Company. Dr LipsonAdvisory Committee: Amgen Inc, Castle Biosciences Incorporated. Dr RibasConsulting Agreements: AstraZeneca Pharmaceuticals LP, Merck, Novartis Pharmaceuticals Corporation; Ownership Interest: cCAM Biotherapeutics, Compugen, Flexus Biosciences, Kite Pharma.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech BioOncology, Merck and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2015
    Expiration date: December 2016

Acknowledge and close

Listen to audio:
Dermatologic Oncology Update, Issue 1, 2015
Released December 2015

Featuring interviews with Drs Jeffrey Weber, Michael A Postow, Evan J Lipson and Antoni Ribas. (Audio Content)

Read print: